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Background:  Clinical outcome of newer-generation drug-eluting stent following rotational atherectomy (RA) remains unclear. We 
investigated clinical outcomes between biodegradable polymer biolimus-eluting stent (BES) and durable polymer everolimus-eluting stent 
(EES) following RA for severe calcified lesions.
methods:  We enrolled 253 consecutive patients treated with only BES (146 patients with 160 lesions) or EES (94 patients with 103 
lesions) following RA. The primary endpoint was the cumulative incidence of major adverse cardiovascular events (MACE) at 2 years, 
defined as a composite of cardiac death, myocardial infarction (MI), clinically-driven target lesion revascularization (CD-TLR), and definite 
stent thrombosis.
results:  Clinical follow-up rate at 2 years was 100 % and angiographic follow-up (6-12 months) rate was 79.4 %. The baseline patients 
and lesions characteristics were similar between the BES and EES groups except for hyperlipidemia. The cumulative incidence of MACE 
were not significantly different (15.7% vs 19.2%, P=0.54). Cumulative incidence of MI, CDTLR, and definite stent thrombosis were not 
significantly different between the 2 groups (2.2% vs. 2.3%, P=0.97; 13.1% vs. 16.1%, P=0.57; 2.9% vs. 1.1%, P=0.37, respectively) Late 
lumen loss was 0.48±0.61mm in BES group and 0.45±0.52mm in EES group (P=0.60).
Conclusion:  Two-year clinical outcome of BES was similar to that of EES in patients needed RA, despite the difference in stent strut 
thickness between BES and EES.
